go to DCU Home
 
..\Images\People\FosterL.gif
  • Foster, Lydia, M.S.
  • Biostatistician
  • Research Instructor, Department of Public Health Sciences
  • College of Medicine, Medical University of South Carolina
  • Phone: 843-876-1129
  • Fax: 843.876.1923
  • Email: fosterl@musc.edu
  • Experience: Phase II-III clinical trials; drugs and device trials
  • Research: Design, conduct and analysis of clinical trials
  • Projects: Neurological Emergencies, Digestive Diseases

Publications
 
  • Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA; Interventional Management of Stroke (IMS) III Investigators.
  • Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.
  • N Engl J Med. 2013 Mar 7;368(10):893-903. doi: 10.1056/NEJMoa1214300. Epub 2013 Feb 7. Erratum in: N Engl J Med. 2013 Mar 28;368(13):1265.

Presentations
 
  • Qureshi AI, Foster LD, Martin RL, Palesch YY, for ATACH II Investigators.
  • Analysis of Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II Trial by As Treated Groups. (Oral)
  • International Stroke Conference, February 2017.
  • Qureshi AI, Foster LD, Martin RL, Palesch YY, for ATACH II Investigators.
  • Effect of Intensive Systolic Blood Pressure Lowering on Hematoma Expansion in Patients with Intracerebral Hemorrhage: Analysis of Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II Trial. (Oral)
  • International Stroke Conference Nursing Symposium, February 2017.
  • Palesch YY, Ramakrishnan V, Foster L, Martin RL, Cassarly C, Barsan WG, Moy CS, Qureshi AI.
  • Outcome analysis for Antihypertensive Treatment for Acute Cerebral Hemorrhage (ATACH) II Trial using repeated systolic blood pressure measures. (Oral)
  • European Stroke Organization Conference, Prague, May 2017.
  • Liebeskind DS, Hill MD, Jovin TG, Menon BK, Nogueira RG, Zaidat OO, Scalzo F, Demchuk AM, Carrozzella J, von Kummer R, Khatri P, Goyal M, Yan B, Foster LD, Yeatts SD, Palesch YY, Broderick JP, Tomsick TA, Yoo AJ, for the IMS III Investigators.
  • Grade 2 or Partial Collaterals in IMS III: Half Full or Half Empty? (Poster)
  • International Stroke Conference, Los Angeles, CA, February 2016.
  • Simpson KN, Broderick JP, Simpson AN, Foster L, Hill MD, Jauch E, Palesch YY, for the IMS III Investigators.
  • Residual Stroke Morbidity and Post-acute Care Cost: the IMS III Economic Data Cohort. (Oral)
  • International Stroke Conference, Los Angeles, CA, February 2016.
  • Foster LD, Durkalski V.
  • Stopping Early in a Non-Inferiority Trial when the Primary Efficacy Outcome is Also the Primary Safety Outcome.
  • . Society for Clinical Trials Annual Meeting. Arlington, VA, 2015 May 19. (oral presentation)
  • Belagaje S, Foster L, Kissela B, Broderick J.
  • The Role of Discharge Disposition in the Interventional Management of Stroke (IMSIII) Trial.
  • American Academy of Neuroradiology Annual Meeting, Washington, DC, 2015 Apr. (poster)
  • Tomsick T, Foster LD, Yeatts SD, Hill MD, Carrozzella J, Liebskind DS, Khatri P, Goyal M, Puetz V, Dzialowski I, Morales H, Demchuck AM, Palesch YY, Broderick JP.
  • Intraarterial (IA) Iodinated Radiographic Contrast Media (IRCM) Effect in the Interventional Management of Stroke (IMS) III Trial.
  • International Stroke Conference, Nashville, TN, 2015 Feb. (poster)
  • Vagal A, Foster L, Menon B, Livorine A, Shi J, Qazi E, Demchuck A, Yeatts S, Hill M, Tomsick T, Goyal M.
  • . Multimodal CT Imaging: Time to Treatment and Outcomes in the Interventional Management of Stroke (IMS) III Trial.
  • International Stroke Conference, Nashville, TN, 2015 Feb. (oral presentation)
  • Vagal A, Menon B, Livorine A, Foster L, Yeatts S, Udgazi E, d'Esterre C, Shu J, Demchuk A, Hill M, Tomsick T, Goyal M.
  • CT Perfusion and Collateral Status in the Interventional Management of Stroke (IMS) III Trial.
  • Presented at the Radiological Society of North America Annual Meeting, Chicago, IL, December 2014. Oral presentation
  • Palesch YY, Yeatts SD, Foster L, Broderick JP for the IMS III Investigators.
  • Endovascular Treatment in the More Severe Stroke Cohort in the Interventional Management of Stroke III Trial May Yield Better Clinical Outcome over 12 Months.
  • Presented at the World Stroke Congress, Istanbul, Turkey. October 2014.
  • Menon B, Yeatts S, Qazi E, Triveti A, Mishra S, Nambiar V, Hill MD, Khatri P, Foster L, von Kummer R, Fan L#, Liebeskind D, Puetz V, Tomsick T, Goyal M, Broderick J, Demchuk A.
  • Clot characteristics on baseline imaging predicts recanalization with IV tPA in the IMS III trial.
  • Presented at the World Stroke Congress, Istanbul, Turkey. October 2014. Poster presentation
  • Simpson AN, Simpson KN, Mauldin PD, Hill MD, Yeatts SD, Spilker JA, Foster LD, Khatri P, Martin R, Jauch EC, Kleindorfer D, Palesch YY, Broderick JP, for the IMS III Investigators.
  • Cost of Inpatient Acute Ischemic Stroke Care in the United States: Findings from the IMS III Trial.
  • Presented at the Academy Health 2014 Annual Research Meeting, San Diego, CA, June 2014.
  • Foster L, Yeatts S, Tomsick T, Broderick J, Palesch Y.
  • Propensity scores facilitate unbiased comparison of endovascular devices in IMS III.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Poster presentation.
  • Menon BK, Qazi E, Nambiar V, Foster LD, Yeatts SD, Liebeskind D, Jovin T, Hill MD, Goyal, M, Tomsick T, Broderick J, Demchuk AM.
  • Differential Effect of Baseline CTA Collateral Status on Clinical Outcomes in Patients Enrolled in the IMS III Trial.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Oral presentation.
  • Simpson KN, Simpson AN, Mauldin PD, Hill MD, Yeatts SD, Spilker JA, Foster LD, Khatri P, Martin R, Jauch EC, Kleindorfer D, Palesch YY, Broderick JP.
  • Drivers of Costs Associated with Reperfusion Therapy in Acute Stroke: the IMS III Trial.
  • Presented at the International Stroke Conference, San Diego, CA, February 2014. Oral presentation.
  • Yeatts SD, Martin RH, Foster LD, Woolson RF, Broderick JP, Palesch YY.
  • The Challenges of Decision-Making Regarding Futility in a Randomized Trial: The IMS III Experience.
  • resented at the International Stroke Conference, Honolulu, HI, 2013. Oral presentation.
    *Among the top 10% of accepted abstracts and invited for presentation at Best of AHA Specialty Conferences at Scientific Sessions 2013 in Dallas, Texas.
  • Khatri P, Yeatts SD, Mazighi M, Broderick JPB, Liebeskind DS, Demchuk AM, Amarenco P, Foster LD, Goyal M, Hill MD, Palesch YY, Jauch EC, Haley EC, Tomsick TA.
  • Time to Angiographic Reperfusion is Highly Associated with Good Clinical Outcome in the Interventional Management of Stroke Phase III Trial.
  • Presented at the International Stroke Conference, Honolulu, HI, 2013. Oral presentation.
  • Liebeskind DS, Tomsick TA, Yeatts S, Foster L, Carrozzella J, Jovin TG, Khatri P, Goyal M, Palesch Y, Broderick JPB.
  • Collaterals in the Interventional Management of Stroke (IMS) III Trial.
  • Presented at the International Stroke Conference, Honolulu, HI, 2013. Poster presentation.
go to DPHS

go to MUSC